Tauroursodeoxycholate-d4
CAT:
804-HY-19696S1
Size:
100 µg
For Laboratory Research Only. Not for Clinical or Personal Use.
Price:
Ask
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


Tauroursodeoxycholate-d4
UNSPSC Description:
Tauroursodeoxycholate-d4 is deuterium labeled Tauroursodeoxycholate. Tauroursodeoxycholate (Tauroursodeoxycholic acid) is an endoplasmic reticulum (ER) stress inhibitor. Tauroursodeoxycholate significantly reduces expression of apoptosis molecules, such as caspase-3 and caspase-12. Tauroursodeoxycholate also inhibits ERK.Target Antigen:
Apoptosis; Caspase; Endogenous Metabolite; ERK; Isotope-Labeled CompoundsType:
Isotope-Labeled CompoundsRelated Pathways:
Apoptosis;MAPK/ERK Pathway;Metabolic Enzyme/Protease;Others;Stem Cell/WntApplications:
Cancer-Kinase/proteaseField of Research:
CancerSolubility:
10 mM in DMSOSmiles:
O=S(CCNC(CC[C@H]([C@H]1CC[C@@]2([H])[C@]3([H])[C@@H](O)C[C@]4([H])C([2H])([2H])[C@H](O)C([2H])([2H])C[C@]4(C)[C@@]3([H])CC[C@]12C)C)=O)(O)=OMolecular Weight:
503.73References & Citations:
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.|[2]Kim SY, et al. Tauroursodeoxycholate (TUDCA) inhibits neointimal hyperplasia by suppression of ERK viaPKCα-mediated MKP-1 induction. Cardiovasc Res. 2011 Nov 1;92(2):307-16.|[3]Qin Y, et al. Tauroursodeoxycholic Acid Attenuates Angiotensin II Induced Abdominal Aortic Aneurysm Formation in Apolipoprotein E-deficient Mice by Inhibiting Endoplasmic Reticulum Stress. Eur J Vasc Endovasc Surg. 2017 Mar;53(3):337-345.Shipping Conditions:
Room temperatureClinical Information:
No Development ReportedCAS Number:
2410279-94-4
